Back to Journals » Drug Design, Development and Therapy » Volume 11

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum]

Authors Jones G, Panova E, Day R

Received 5 December 2017

Accepted for publication 5 December 2017

Published 15 December 2017 Volume 2017:11 Pages 3589—3590

DOI https://doi.org/10.2147/DDDT.S158965

Jones G, Panova E, Day R. Drug Des Devel Ther. 2017;11:3077–3081.

On page 3078, Table 1, Abbreviation list, expansion for FBX was incorrectly listed as feboxustat, the correct spelling is febuxostat.

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]